Sammy Chebon

Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study

Steven W. Pipe, Midori Shima, Michaela Lehle et al. · The Lancet Haematology · 2019 · 373 citations · Full text

Haven 4, Hematology, Non-randomised Phase 3 +2

Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies

Michael U. Callaghan, Claude Négrier, Ido Paz‐Priel et al. · Blood · 2020 · 270 citations · Full text

Thrombosis, Antibiotics, Pediatric Hematology +15

Immunogenicity of Emicizumab in People with Hemophilia A (PwHA): Results from the HAVEN 1-4 Studies

Ido Paz‐Priel, Tiffany Chang, Elina Asikanius et al. · Blood · 2018 · 58 citations

Low immunogenicity of emicizumab in persons with haemophilia A

Christophe Schmitt, Thomas Emrich, Sammy Chebon et al. · Haemophilia · 2021 · 54 citations · Full text

The effect of emicizumab prophylaxis on long‐term, self‐reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies

Mark W. Skinner, Claude Négrier, Ido Paz‐Priel et al. · Haemophilia · 2021 · 52 citations · Full text